Universidade Federal de Itajubá, campus Itabira, Laboratório de Bioengenharia, Rua Irmã Ivone Drumond, 200, Itabira, Minas Gerais, Brazil.
Universidade Federal de Itajubá, campus Itabira, Laboratório de Bioengenharia, Rua Irmã Ivone Drumond, 200, Itabira, Minas Gerais, Brazil.
Biomed Pharmacother. 2020 Nov;131:110695. doi: 10.1016/j.biopha.2020.110695. Epub 2020 Sep 10.
The unique properties of polymer-hybrid nanosystems enable them to play an important role in different fields such as biomedical applications. Hybrid materials, which are formed by polymer and inorganic- or organic-base systems, have been the focus of many recently published studies whose results have shown outstanding improvements in drug targeting. The development of hybrid polymer materials can avoid the synthesis of new molecules, which is an overall expensive process that can take several years to get to the proper elaboration and approval. Thus, the combination of properties in a single hybrid system can have several advantages over non-hybrid platforms, such as improvements in circulation time, structural disintegration, high stability, premature release, low encapsulation rate and unspecific release kinetics. Thus, the aim of the present review is to outline a rapid and well-oriented scenario concerning the knowledge about polymer-hybrid nanoparticles use in biomedical platforms. Furthermore, the ultimate methodologies adopted in synthesis processes, as well as in applications in vitro/in vivo, are the focus of this review.
聚合物-杂化纳米系统的独特性质使它们能够在生物医学等不同领域发挥重要作用。由聚合物和无机或有机基系统形成的杂化材料一直是许多最近发表的研究的焦点,这些研究的结果表明在药物靶向方面有了显著的改进。杂化聚合物材料的发展可以避免合成新的分子,这是一个整体昂贵的过程,可能需要数年时间才能进行适当的阐述和批准。因此,在单个杂化系统中结合多种性质可能具有许多优于非杂化平台的优势,例如循环时间延长、结构崩解、高稳定性、过早释放、低封装率和非特异性释放动力学。因此,本综述的目的是概述在生物医学平台中使用聚合物-杂化纳米粒子的相关知识,快速且针对性强。此外,本综述还重点介绍了合成过程中采用的最终方法,以及体外/体内应用。
Biomed Pharmacother. 2020-11
Drug Discov Today. 2017-6-8
Biotechnol J. 2013-7-11
J Microbiol Methods. 2019-3-18
Int J Pharm. 2013-9-13
Adv Protein Chem Struct Biol. 2015
Colloids Surf B Biointerfaces. 2011-3-2
Pharmaceutics. 2025-6-19
ACS Appl Mater Interfaces. 2025-7-2
Int J Nanomedicine. 2025-5-26
Int J Nanomedicine. 2025-5-6
Naunyn Schmiedebergs Arch Pharmacol. 2025-3-3